We have recently shown that lymphocyte and monocyte recovery by day þ 100 are associated with survival post myeloablative allogeneic hematopoietic transplant for acute leukemia. We hypothesized that lymphocyte and monocyte recovery would have a similar impact on survival in the reduced intensity setting. To test this hypothesis, we analyzed clinical data from 118 consecutive fludarabine/melphalan-conditioned patients by correlating peripheral blood absolute lymphocyte counts and monocyte counts (ALC and AMC, respectively) at days þ 15, þ 30, þ 60 and þ 100 with the outcomes. Multivariate analysis revealed that day þ 100 AMC (risk ratio (RR) 0.22, 95% confidence interval (CI) 0.07-0.73, P ¼ 0.01) and mild chronic GVHD (RR 0.09, 95% CI 0.005-0.43, P ¼ 0.008) were independently associated with survival. To explore whether the patterns of lymphocyte and monocyte recovery had a prognostic value, we performed unsupervised hierarchical clustering on the studied hematopoietic parameters and identified three patient clusters, A-C. Patient clusters A and B both had improved OS compared with cluster C (77.8 months vs not reached vs 22.3 months, respectively, Po0.001). No patient in cluster C had a day þ 100 AMC 4300. Both severe acute GVHD and relapse occurred more frequently in cluster C. Our data suggest that patients with low AMC by day þ 100 post fludarabine/melphalanconditioned allogeneic hematopoietic SCT may be at risk for poor outcomes. Keywords: monocyte; lymphocyte; immune reconstitution; reduced intensity allogeneic hematopoietic SCT; GVHD; relapse INTRODUCTION Rapid immunologic reconstitution is required in order to avoid the three most frequent causes of mortality post allogeneic hematopoietic stem cell transplant (HSCT): infections, GVHD and relapse.
INTRODUCTION
Rapid immunologic reconstitution is required in order to avoid the three most frequent causes of mortality post allogeneic hematopoietic stem cell transplant (HSCT): infections, GVHD and relapse. 1 Reduced intensity conditioning (RIC) regimens may be associated with more rapid immunologic reconstitution than myeloablative conditioning via mechanisms such as the preservation of T-celldependent mitogenic responses 2 , thymic function 3 and increased early T-cell repertoire complexity. 4 Other studies have not demonstrated significantly improved immune reconstitution with RIC, 5, 6 making this area a subject of continued debate (reviewed by Jimenez et al. 7 ). While many previous studies of immune reconstitution post HSCT have focused on lymphocyte subset recovery, [8] [9] [10] [11] [12] [13] [14] [15] [16] we have previously shown that combined monocyte and lymphocyte recovery also has an impact on survival post myeloablative HSCT in acute leukemia due to a reduction in nonrelapse mortality. 17 Here, we test the hypothesis that both lymphocyte and monocyte recovery are similarly associated with survival in patients undergoing RIC allogeneic HSCT with fludarabine and melphalan.
PATIENTS AND METHODS

Patient characteristics
Patients in this cohort underwent RIC allogeneic HSCT as a part of therapy for myeloid (N ¼ 87) and lymphoid (N ¼ 31) malignancies from 2001-2010.
One hundred and eighteen consecutive patients were identified for the study, and all were included for analysis. All patients gave written consent to use their medical records for research. No patients were lost to followup. Approval for the retrospective review of these records was obtained from the Mayo Clinic Institutional Review Board and was performed in accordance with US federal regulations and the Declaration of Helsinki.
End points
The primary end point of the study was to assess the role of peripheral blood lymphocyte and monocyte recovery at days þ 15, þ 30, þ 60 and þ 100 post haematopoietic SCT on OS. The absolute lymphocyte count (ALC) and absolute monocyte count (AMC) were recorded from the complete blood cell count 18 at days þ 15, þ 30, þ 60 and þ 100 post haematopoietic SCT.
Statistical analysis OS estimates were determined using the approach of Kaplan and Meier. 21 Differences between survival curves were tested for statistical significance using the two-tailed log-rank test. Cox proportional hazard models were used for univariate survival analysis on continuous variables as well as for the multivariate analysis. Cutoffs for survival analyses were the same as used in our previous analysis: 17 0.3 Â 10 9 cells/L for both ALC and AMC. Associations between categorical variables were determined by Fisher's exact test. Correlations between continuous variables were determined by Spearman's r. Owing to multiple comparisons creating the potential for false-positive associations with this analysis, a Bonferroni correction (Po0.05/118) was applied. Unsupervised hierarchical clustering of ALC and AMC data at days þ 15, þ 30, þ 60 þ and þ 100 was completed in order to identify the natural subgroups of patients with different patterns of immune recovery within the cohort and was performed according to Ward's method. 22 All the P-values represented were two-sided, and statistical significance was declared at Po0.05.
RESULTS
Patient characteristics
Patient characteristics are described in Table 1 . The median age of the cohort was 58 years with a male predominance (63.5%). The conditioning regimen consisted of fludarabine 25 mg/m 2 i.v. on days À 6 through À 2, and melphalan 70 mg/m 2 i.v. on days À 3 and À 2. All patients received consistent supportive care including calcineurin inhibitor-based GVHD prophylaxis. The majority of the stem cell grafts were derived from fully matched related donors (69%), and only eight received stem cells from a marrow source. In this cohort, 23 (19.5%) patients experienced relapse of their malignancy. In all, 60 patients have died at the time of analysis with a median follow up of 40 months for the living. Of the 60 who have died, the primary cause of death was nonrelapse mortality in 42 patients and relapse in 18 patients. The median OS of the entire cohort is 60.8 months, with B30% patients experiencing long-term survival (beyond 5 years) by Kaplan-Meier estimates.
ALC and AMC recovery, RFS, and OS: univariate analysis Achievement of ALC and AMC 4 0.3 Â 10 9 cells/L at day þ 100 were associated with improved RFS (P ¼ 0.03 and Po0.001, respectively). Very early ALC and AMC recovery at the day þ 15 time point was not associated with improved OS (Figure 1 ). At all time points after day þ 15, an ALC 40.3 Â 10 9 cells/L was significantly associated with improved OS. However, an AMC 40.3 Â 10 9 cells/L was statistically significant (P ¼ o0.001) only at the day þ 100 time point. In contrast to the results from our myeloablative cohort, the day þ 60 AMC (P ¼ 0.006) and day þ 100 AMC (P ¼ 0.004) were associated with improved survival when analyzed as continuous variables (others not shown). Additional variables associated with OS included the year of transplant, grade of acute GVHD and severity of chronic GVHD (Table 1) . Age, sex, disease, donor type, stem cell source, disease status at transplant, number of CD34 þ cells infused, time to neutrophil and platelet engraftment, and CMV reactivation did not impact OS.
ALC and AMC recovery and OS: multivariate analysis Variables demonstrating a significant survival differences in the univariate analysis (above hematopoietic parameters, year of transplant, grade of acute GVHD and severity of chronic GVHD) were included in a multivariate model to determine the independent prognostic factors for survival. Through backward selection, ALC40.3 Â 10 9 /L at day þ 100, AMC at days þ 60 and þ 100 as continuous variables, and chronic GVHD remained statistically significant in the proportional hazards model. In the final model, day þ 60 AMC was omitted due to multicollinearity and lesser degree of survival association in the univariate analysis. The final model revealed that lymphocyte and monocyte recoveries at day þ 100 and eventual development of mild chronic GVHD were independent prognostic factors for improved survival (Table 2) .
Associations with ALC and AMC recovery
We assessed the correlations between ALC and AMC recovery as continuous variables with time to neutrophil and platelet engraftment, CD34 þ cell dose, CMV reactivation and severity of acute and chronic GVHD. Statistically significant correlations of at least moderate intensity after Bonferroni correction are listed in Table 3 . Day þ 15 ALC and AMC are strongly and positively correlated with each other and negatively correlated with the number of days to neutrophil and platelet engraftment, suggesting these values are associated with initial engraftment in general. Even though independent in the multivariate survival analysis, the day þ 100 ALC and AMC show a moderate positive association (Spearman's r ¼ 0.5). Patients who achieved a day þ 100 ALC40.3 Â 10 9 cells/L were likely to also achieve a day þ 100 AMC4 0.3 Â 10 9 cells/L (82 patients, P ¼ 0.001). Neither CMV reactivation nor the severity of acute or chronic GVHD retained associations with ALC and AMC recovery after Bonferroni correction.
We determined the association of immunosuppressive therapy medications on ALC and AMC recovery, both as continuous variables and at the threshold level of 0.3 Â 10 9 cells/L. No significant association was found between calcineurin inhibitors or prednisone dose with ALC or AMC recovery, both as continuous variables and as a cutoff of 0.3 Â 10 9 cells/L (not shown). In nine patients receiving mycophenolate mofetil (eight of whom were also receiving prednisone), more severe monocytopenia and lymphopenia was observed (P ¼ 0.03 and P ¼ 0.02, respectively) at the day þ 100 time point. No patients were receiving sirolimus or other novel systemic immune modulators at the time points assessed.
Patterns of ALC and AMC recovery and survival To determine whether any inherent patterns in the timing of combined ALC and AMC recovery within the first 100 days post transplant could have an impact on survival after fludarabine and melphalan conditioning, we performed unsupervised hierarchical clustering (Figure 2 ) on the longitudinal hematopoietic parameters studied in this cohort. We analyzed the outcomes of patient clusters at a threshold of both three and four clusters and determined that the relevant outcomes were best described as three patient clusters, which we have labeled A, B and C. Cluster A patients were characterized by early, stable engraftment throughout time points tested. Cluster B patients had low ALC and AMC at day þ 15 but generally had counts above the cutoff at the rest of the measured time points. Cluster C patients had good early count recovery but a majority had a low ALC at day þ 100 and zero patients had an AMC 40.3 Â 10 9 /L at day þ 100. Patient clusters A and B had significantly improved OS compared with cluster C (median survival 77.8 months vs not reached vs 22.3 months, respectively, Po0.001, Figure 3 ). This survival difference between the patient clusters visually appears to be due to the achievement of our cutoff for ALC and AMC recovery at both the day þ 60 and day þ 100 time points in this analysis.
Morbidity and mortality in patient clusters Cluster C showed an increase in relapse compared with clusters A and B (P ¼ 0.003, Figure 4 ). Clusters A and B, the two clusters showing the best OS, were the only patient clusters to not have any patients experiencing grade 4 acute GVHD (P ¼ 0.02, Figure 5 ). Cluster C had the highest proportion of patients with CMV reactivation (64% compared to 22.5% in A and 40% in B, P ¼ 0.02), and the highest proportion of patients taking mycophenolate mofetil at day þ 100 (28.6% vs 2.5% in A and 11.4% in B, P ¼ 0.02). Cluster A had the highest proportion of severe chronic GVHD (P ¼ 0.02, Figure 6 ), which may explain the lack of long-term survivors relative to cluster B.
Clinical and hematopoietic factors in the 'no cluster' group Twenty nine patients could not be clustered by the algorithm due to early deaths, resulting in missing data and a subsequent inability to be included in the clustering. There was no significant difference in this 'no cluster' group vs those patients who could be clustered based on the following factors: related or unrelated stem cell source (P ¼ 0.63), sex of the recipient (P ¼ 0.15), disease type (P ¼ 0.99), CD34 þ cell dose (P ¼ 0.44), and age at HSCT (P ¼ 0.78). Cluster B and the 'no cluster' groups were the only groups where BM as a stem cell source was present. The 'no cluster' group was the least likely to achieve ALC recovery by days þ 30 and þ 60 (P ¼ 0.002 and Po0.001, respectively). As depicted in Figure 5 , the 'no cluster' group experienced an increased occurrence of grade 4 acute GVHD relative to other patient clusters. In all, 50% of the patients in the 'no cluster' group experienced grade IV acute GVHD. Relapse did not occur in the 'no cluster' group; all deaths were due to toxicities of the transplant.
Contrasted and combined analysis of ALC and AMC recovery in myeloablative and RIC cohorts Compared with our previous myeloablative cohort, 17 this RIC cohort had a slightly higher AMC at day þ 15 (median 0.45 vs 0.33 Â 10 9 /L, P ¼ 0.036) and slightly higher ALC at day þ 100 (median 0.83 vs 0.71 Â 10 9 /L, P ¼ 0.047). Otherwise, there were no significant differences in lymphocyte and monocyte recovery identified between the cohorts. When we combined ALC and AMC data from both our RIC and myeloablative cohorts, the only longitudinal hematpoietic parameter associated with survival as a continuous value was the day þ 100 AMC (risk ratio ¼ 0.24, 95% confidence interval 0.1-0.58, P ¼ 0.001). At the threshold of 0.3 Â 10 9 /L, AMC at days þ 30 (P ¼ 0.005), þ 60 (P ¼ 0.005) and þ 100 (Po0.001), as well as ALC at day þ 60 (P ¼ 0.02), were associated with improved survival.
DISCUSSION
In this study, we show prognostic patterns of combined lymphocyte and monocyte recovery in association with reduced nonrelapse mortality in the RIC setting, with findings similar to those we have previously reported in a cohort of patients undergoing myeloablative conditioning. 17 Lymphocyte and monocyte recovery at day þ 100 was associated with improved OS, although lymphocyte recovery was of borderline statistical significance. In contrast to our previous report, achievement of an ALC and AMC 40.3 Â 10 9 /L at day þ 100 was associated with improved RFS in this cohort. A separate study of RIC conditioning with BU, fludarabine and alemtuzumab did not show an improvement in RFS with ALC recovery, although the lymphocyte depletion and delayed immune recovery that can occur after alemtuzumab administration may have played a role in this result. 23 Patients who demonstrated the poorest lymphocyte and monocyte recovery, cluster C and the 'no cluster' groups, experienced more severe acute GVHD compared with the other patients. The use of mycophenolate mofetil was significantly associated with lymphopenia and monocytopenia in this cohort. It is possible that ALC and AMC recovery may be independent of corticosteroid dose during the treatment of GVHD, although this will require validation. To our knowledge, post transplant monocyte levels have not previously been associated with acute GVHD, although pretransplant recipient monocyte counts have previously been reported to increase this risk. 24 Poor platelet recovery is similarly associated with increased nonrelapse mortality due to acute GVHD, 25 and whether any impact of ALC and AMC recovery on acute GVHD is also associated with or independent of platelet recovery will be determined in a future study. Allograft monocytes can suppress T-cell proliferation in a dose-dependent fashion, potentially protecting from GVHD effects. 26, 27 Finally, whether or not the contribution of allograft monocyte content could also play a role in the development of acute GVHD, RFS or OS in this cohort is also not yet known but is under evaluation. If an association is identified, it may be possible to modify the collection strategies or engineer the graft to support monocyte regulation of alloreactivity, reduce acute GVHD and improve immune reconstitution. Cluster A patients, who had the best ALC and AMC recovery of all the other patient clusters, also experienced the most moderate/ severe chronic GVHD. Mortality from chronic GVHD and its treatment may have contributed to their nonstatistically significantly inferior survival compared to the best performers in this cohort: Cluster B patients. This finding raises a question of whether a pattern of lymphocyte and monocyte recovery that is 'too good' exists. One study has demonstrated an association of increased BM and peripheral blood CD14 þ CD86 þ monocytes with chronic GVHD. 28 Additionally, the improved recovery of CD14 þ CD16 þ monocytes post allogeneic HSCT has recently been associated with less extensive chronic GVHD. 29 Our findings are limited in that we did not have blood samples available for subset analysis or functional testing, but potential cellular predictors of subsequent chronic GVHD and its treatment would be of significant clinical utility. In summary, this study adds to the increasing evidence supporting monocyte populations as important determinants of 
